Is the determination of the soluble interleukin-2 receptor after application of interleukin-2 receptor antibodies still appropriate for immunological monitoring after renal transplantation?

Urologia Internationalis

Volumn 77, Issue 3, 2006, Pages 232-239

  Hamza, Amir ^a   Fischer, Kersten ^a   Loertzer, Hagen ^a   Fornara, Paolo ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Antibody basiliximax; Immunological monitoring; Interleukin 2 receptor; Kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SOLUBLE INTERLEUKIN 2 RECEPTOR; TACROLIMUS;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANTIBODY DETECTION; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; FEMALE; FEVER; GERMANY; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYELONEPHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 33750002207     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094815     Document Type: Article

References (24)

1. Fischer K, Hamza A, Eismann R, Amoury M, Heynemann H, Fornara P: Differential diagnostic use of interleukin patterns in patients being monitored after transplantation. Clin Chim Acta 2001;310:71-80.
2. Daniel V, Pasker S, Wiesel M, et al: Cytokine monitoring of infection and rejection in renal transplant recipients. Transplant Proc 1995;27:884-886.
3. Van Dorp WT, van Wieringen PAM, Marselis-Jonges E, et al: Cytomegalovirus directly enhances MHC class I and intercellular adhesion molecule-1 expression on cultured proximal tubular epithelial cells. Transplantation 1993;55:1367-1371.
4. Fricke L, Steinhoff J, Hartwig-Weber I, Bein G: Bedeutung risikoadaptierter antiviraler Prophylaxe und moderner Virusdiagnostik für das Organüberleben nach Nierentransplantation. Dtsch Med Wochenschr 1997;122:565-571.
5. Grimminger F, Mayer K, Seeger W: Gibt es eine gesicherte Immuntherapie bei Sepsis? Internist 1997;38:541-552.
6. Kunz D, Pross M, König W, Lippert H, Manger T: Diagnostic relevance of procalcitonin, IL-6 and cellular immune status in the early phase after liver transplantation. Transplant Proc 1998;30:2398-2399.
7. Werner M, Otto U, Schreiter D, et al: Der immunologische Risikopatient bei Sepsis und Transplantation. Transplantationsmedizin 2003;15:70-90.
8. Whicher JT: Akute-Phase-Proteine: Grundlagen und diagnostische Bedeutung. J Lab Med 1996;20:597-608.
9. Müller TF: Immunologisches Monitoring nach Organtransplantation; Lison AE (ed): Beiträge zur Transplantations-Medizin. Lengerich, Pabst Science, 1998, p 36.
10. Reinke P: Antikörper bei Transplantationen. Target Forum 2000;1:4-11.
11. Ter Meulen CG, Göertz JHC, Klasen IS, et al: Decreased renal excretion of soluble interleukin-2 receptor-α after treatment with daclizumab. Kidney Int 2003;64:697-703.
12. Bock GH, Neu L, Long C, Patterson LT, Korb S, Gelpi J, Nelson DL: An assessment of serum and urine soluble interleukin-2 receptor concentrations during renal transplant rejection. Am J Kidney Dis 1994;23:421-426.
13. Bürger A, Stock B, Grunewald RW, Franz HE, Keller F: Ratio of soluble interleukin-2 receptor over interleukin-6 as a tool to differentiate infection and acute rejection after renal transplantation. Transplantationsmedizin 1996;8:111-118.
14. Casiraghi F, Ruggenenti P, Noris M, Locatelli G, Perico N, Perna A, Remuzzi G: Sequential monitoring of urine-soluble interleukin-2 receptor and interleukin-6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Transplantation 1997;63:1508-1514.
15. Gupta RK, Jain M, Sharma RK: Serum and urinary interleukin-2 levels as predictors in acute renal allograft rejection. Indian J Med Res 2004;119:24-27.
16. Kaden J, Schütze B, May G: A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients. Transpl Int 1996;9(suppl 1):63-67.
17. Kumano K, Irie A, Mashimo S, Endo T, Koshiba K: Changes in urinary interleukin-2 in kidney transplant recipients. Transplant Proc 1996;28:1248-1249.
18. Mehta R, Shah G, Adler W, Kittur D: Soluble interleukin-2 receptor levels in renal transplant recipients. Clin Transplant 2004;18:67-71.
19. Montagnino G, Tarantino A, Grignani S, Braga M, Ponticelli C: Soluble interleukin-2 receptor levels in renal transplantation: comparison between clinical and laboratory analysis. Clin Transplant 1995;9:25-30.
20. Trochu JN, Denis M, Auget JL, et al: Soluble interleukin-2 receptor (Tac chain) is not a reliable marker in kidney transplant recipient monitoring. Transpl Int 1992;5:145-150.
21. Näther S, Schulz T, Anger H, et al: Immune status of patients on continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1997;27(suppl 1):A102.
22. Ter Meulen CG, Jacobs CWM, Wetzels JFM, Klasen IS, Hilbrands LB, Hoitsma AJ: The fractional excretion of soluble interleukin-2 receptor-α is an excellent predictor of the interleukin-2 receptor-α status after treatment with daclizumab. Transplantation 2004;77:281-286.
23. Rebhandl W, Felberbauer FX, Resch S, et al: Value of circulating immune parameters in renal transplantation. Transplant Proc 1997;29:1881-1885.
24. Yang J, Li XW, Zheng FL, Bi ZQ: Evaluation of serum immunological parameters in acute renal allograft rejection. Transplant Proc 1996;28:1443-1444.